IP Library Granted Patent US 8,658,603
Granted Patent B2
US 8,658,603 · App. 13/331,354 · Granted Feb 25, 2014

Compositions and methods for inducing an immune response

Inventors: Joseph Holoshitz (Ann Arbor, MI); Song Ling (Ypsilanti, MI); Xiujun Pi (Ann Arbor, MI); Denise de Almeida (Dearborn, MI); Chaim Gilon (Jerusalem, IL); Amnon Hoffman (Jerusalem, IL)
Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,658,603
App. No.
13/331,354
Granted
Feb 25, 2014
Kind
B2
Abstract

The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Claims (13)

1. A method of inducing an immune response in a subject comprising administering to the subject an effective dose of a composition comprising an isolated cyclic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.:1-6, 13 and 14 under conditions such that an immune response is generated in the subject.

2. The method of claim 1 , wherein the immune response comprises expansion of Th17 cells.

3. The method of claim 2 , wherein the Th17 cells are pathogen-specific.

4. The method of claim 1 , wherein the immune response comprises inhibition of T regulatory cell differentiation or activity.

5. The method of claim 1 , wherein the immune response comprises enhanced nitric oxide signalling.

6. The method of claim 1 , wherein the immune response comprises enhanced production of IL-6.

7. A method of inhibiting T cell tolerance in a subject comprising administering to the subject an effective dose of a composition comprising an isolated cyclic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 1-6, 13 and 14 under conditions such that T cell tolerance is reduced in the subject.

8. The method of claim 1 , wherein the cyclic peptide is:

wherein n is selected from the group consisting of 2, 4 and 6.

9. The method of claim 1 , wherein the cyclic peptide is generated using a method selected from the group consisting of a urea backbone cyclic protocol, an amide backbone-to-side chain cyclic peptide synthesis scheme, a peptide stapling protocol, and a combination thereof.

10. The method of claim 7 , wherein the cyclic peptide is:

wherein n is selected from the group consisting of 2, 4 and 6.

11. The method of claim 7 , wherein the cyclic peptide is generated using a method selected from the group consisting of a urea backbone cyclic protocol, an amide backbone-to-side chain cyclic peptide synthesis scheme, a peptide stapling protocol, and a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: HOLOSHITZ, JOSEPH; LING, SONG; PI, XIUJUN; DE ALMEIDA, DENISE
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 027754/0102 →
CONFIRMATORY LICENSE Recorded Jan 6, 2012
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027490/0566 →
Continuity (3)
Continuation In Part 13162382 · Jun 16, 2011
Provisional Application 61355413 · Jun 16, 2010
Related Publication 20120141516A1 · Jun 7, 2012